CLAIMS

1. An antibody composition comprising polyclonal ovine antibodies, for use in the prevention or treatment of *C. difficile* infection wherein the antibodies bind to a *C. difficile* toxin; optionally wherein said prevention or treatment is by oral delivery of the antibody composition.

~~2. The antibody composition for use according to Claim 1, wherein the antibodies are polyclonal antibodies.~~

~~3.~~2. The antibody composition for use according to ~~any preceding claim~~Claim 1, wherein the antibodies bind to a *C. difficile* toxin selected from the group consisting of: *C. difficile* Toxin A, *C. difficile* Toxin B, and *C. difficile* Binary Toxin.

~~4.~~3. The antibody composition for use according to ~~any~~ Claim ~~3~~2, wherein the antibodies bind to *C. difficile* Toxin A and to *C. difficile* Toxin B.

~~5.~~4. The antibody composition for use according to ~~any~~ Claim ~~3~~2, wherein the antibodies bind to *C. difficile* Toxin A and to *C. difficile* Binary Toxin.

~~6.~~5. The antibody composition for use according to ~~any~~ Claim ~~3~~2, wherein the antibodies bind to *C. difficile* Toxin B and to *C. difficile* Binary Toxin.

~~7.~~6. The antibody composition for use according to any of Claims 1-~~5~~4, wherein the *C. difficile* toxin is a Toxin A selected from the following group: Toxinotype 0, Toxinotype III and Toxinotype V.

~~8.~~7. The antibody composition for use according to any of Claims 1-~~4~~ 3 or Claim ~~6~~5, wherein the *C. difficile* toxin is a Toxin B selected from the following group: Toxinotype 0, Toxinotype III, Toxinotype V, and Toxinotype VIII (eg. from *Clostridium difficile* ribotype 017).

~~9.~~8. A pharmaceutical composition for oral delivery, comprising the antibody composition as defined in any of Claims 1 to ~~8~~7, together with at least one component selected from a buffer, excipient and/or salt; optionally including one or more means for protecting said antibody composition from trypsin and/ or chymotrypsin and/ or stomach acid.

~~10.~~9. A pharmaceutical composition for oral delivery according to Claim ~~9~~8, wherein the one or more means for protecting said antibody composition from trypsin and/ or chymotrypsin and/ or stomach acid is selected from:

(a) a polypeptide which binds specifically to and suppresses or inactivates the proteolytic activity of trypsin and/ or chymotrypsin; and/ or

(b) an antibody that binds to trypsin and/ or chymotrypsin and suppresses or inactivates the protease activity of said trypsin and/ or chymotrypsin; and/ or

(c) a delivery vehicle selected from a liposome, a microsome, a nanosome, a pellet, a granular matrix, a bead, a microsphere, a nanoparticle formulation, or an aqueous solution; and/ or

(d) an antacid molecule; and/ or

(e) a PEGylation moiety covalent attached to one of more of the antibodies.

~~11.~~10. A pharmaceutical composition for oral delivery according to Claim ~~9~~8 or Claim ~~10~~9, wherein the composition includes an antacid molecule and:

(a) a polypeptide which binds specifically to and suppresses or inactivates the proteolytic activity of trypsin and/ or chymotrypsin; or

(b) an antibody that binds to trypsin and/ or chymotrypsin and inactivates the protease activity of said trypsin and/ or chymotrypsin.

~~12.~~11. Use of the antibody composition according to any of Claims 1-~~7~~8 or a pharmaceutical composition according to any of Claims ~~9~~8-~~10~~11 in the manufacture of a medicament for prevention or treatment of *C. difficile* infection, optionally wherein said medicament is to be administered via oral administration.

~~13.~~12. A pharmaceutical composition according to any of Claims ~~9~~8-~~10~~11, for use in the prevention or treatment of *C. difficile* infection.

~~14.~~13. A method of producing ovine antibodies for use in the oral antibody composition according to any of Claims 1-~~7~~8, or for use in a pharmaceutical composition according to any of Claims ~~9~~8-~~10~~11, wherein the ovine antibodies are elicited by a sheep in response to an immunogen comprising a *C. difficile* toxin or a fragment thereof.

~~15.~~14. A method of producing ovine antibodies for the use ~~in the method~~ of Claim ~~12~~11, said method comprising (i) administering an immunogen comprising a *C. difficile* toxin or a fragment thereof to a sheep, (ii) allowing sufficient time for the

generation of antibodies in the sheep, and (iii) obtaining the antibodies from the sheep.

~~16.~~15. The method according to Claim ~~14~~13 or Claim ~~15~~14, wherein the immunogen is a *C. difficile* toxoid.

~~17.~~16. A use according to Claim ~~12~~11 or a pharmaceutical composition for use according to Claim ~~13~~12, wherein said one or more trypsin and/ or chymotrypsin inhibitor and/ or antacid molecule is to be administered prior to, simultaneously with, or subsequent to administration of the antibody composition.

~~18.~~17. An antibody composition for use according to any of Claims 1-~~8~~ or a pharmaceutical composition for use according to Claim ~~13~~12, wherein said oral administration is performed prior to, simultaneously with, or subsequent to non-oral administration of a second ovine antibody composition wherein said second ovine antibody composition comprises ovine antibodies as defined in any of Claims 1-~~8~~;
preferably wherein said non-oral (eg. systemic) administration is performed prior to said oral administration

~~20.~~18. A use according to Claim ~~12~~11 wherein said oral administration is to be performed prior to, simultaneously with, or subsequent to non-oral administration of a second ovine antibody composition wherein said second ovine antibody composition comprises ovine antibodies as defined in any of Claims 1-~~8~~;
preferably wherein said non-oral (eg. systemic) administration is to be performed prior to said oral administration.

~~21.~~19. An antibody composition for use according to any of Claims 1-~~8~~ or 17~~18~~ or a pharmaceutical composition for use according to Claim ~~13~~12 or Claim ~~18~~17, or a use according to Claim 11~~12~~ or Claim ~~20~~19, wherein the subject to be treated or protected is a subject in one or more or the following categories: hospitalised; over 65 or 70 years' old; receiving broad-range spectrum antibiotics; having previous CDI history/ infection; having close proximity to symptomatic CDI patients; having mild to moderate disease severity; presenting as asymptomatic but considered at high risk of relapse (eg. because of one or more relapse episodes); having close proximity to CDI outbreak areas or patients.